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The role of glucocorticoids in the regulation of apoptosis remains incongruous. Here, we demonstrate that corticosterone protects
neurons from apoptosis by a mechanism involving the cyclin-dependent kinase inhibitor p21Waf1/Cip1. In primary cortical neurons,
corticosterone leads to a dose- and Akt-kinase-dependent upregulation with enhanced phosphorylation and cytoplasmic appearance of
p21Waf1/Cip1 at Thr 145. Exposure of neurons to the neurotoxin ethylcholine aziridinium (AF64A) results in activation of caspase-3 and a
dramatic loss of p21Waf1/Cip1 preceding apoptosis in neurons. These effects of AF64A are reversed by pretreatment with corticosterone.
Corticosterone-mediated upregulation of p21Waf1/Cip1 and neuroprotection are completely abolished by glucocorticoid and mineralo-
corticoid receptor antagonists aswell as inhibitors of PI3- andAkt-kinase. Both germline and somatically inducedp21Waf1/Cip1 deficiency
abrogate the neuroprotection by corticosterone, whereas overexpression of p21Waf1/Cip1 suffices to protect neurons from apoptosis. We
identify p21Waf1/Cip1 as a novel antiapoptotic factor for postmitotic neurons and implicate p21Waf1/Cip1 as the molecular target of neuro-
protection by high-dose glucocorticoids.
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Introduction
Glucocorticoids act as a double-edged sword in the regulation of
apoptosis. For example, glucocorticoids induce apoptosis in in-
flammatory and immune cells such as thymocytes, myeloma
cells, and peripheral blood monocytes, whereas concomitantly
they protect those cells and tissues in which the inflammation
takes place (for review, see Amsterdam et al., 2002). The situation
may be similar in the CNS [for review, see A´braha´m et al. (2001)
and Lee et al. (2002)]: on the one hand, glucocorticoids enhance
neuronal cell death (Behl et al., 1997a), and glucocorticoid recep-
tor antagonists are protective, for example, during oxidative
stress (Behl et al., 1997b; McCullers et al., 2002). On the other
hand, high-dose glucocorticoid pretreatment interferes with ap-
optotic death in glioma cells and oligodendrocytes and reduces
ischemic brain damage and retinal light damage (Tuor, 1997;
Gorman et al., 2000; Melcangi et al., 2000; Wenzel et al., 2001;
Limbourg et al., 2002).
Potential antiapoptotic mechanisms of glucocorticoids in-
volve loss ofmitochondrial membrane potential, upregulation of
antiapoptotic proteins Bcl-2 and Bcl-xL, and activation of the
phosphatidylinositol 3-Akt-kinase (PI3-Akt-kinase) pathway
(Evans-Storms and Cidlowski, 2000; Gorman et al., 2000; Bailly-
Maitre et al., 2001; Sasson et al., 2001, 2002). In linewith the latter
notion, the PI3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-
1(4H)-benzopyran-4-one hydrochloride (LY294002) com-
pletely abolishes any protective effect of glucocorticoids in mod-
els of stroke andmyocardial infarction (Hafezi-Moghadam et al.,
2002; Limbourg et al., 2002). Interestingly, glucocorticoids acti-
vate PI3-Akt-kinase in a ligand-dependent, nongenomicmanner
(Limbourg et al., 2002) similar to that of the estrogen receptor
(Simoncini et al., 2000).
Interestingly, the cyclin-dependent kinase (cdk) inhibitor
p21Waf1/Cip1 gene contains a glucocorticoid receptor response re-
gion in its promoter region, and dexamethasone significantly in-
creases expression of p21Waf1/Cip1 in non-neuronal cells (Cha et
al., 1998; Cram et al., 1998; Terada et al., 2001). Moreover,
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p21Waf1/Cip1 is phosphorylated by Akt-kinase at a consensus thre-
onine residue (T145), leading to cytoplasmic localization and acti-
vation of p21Waf1/Cip1 (Zhou et al., 2001). Notably, p21Waf1/Cip1
functions not only as a cell cycle inhibitor but also as an inhibitor of
caspase-3 and apoptotic cell death and hence is an attractive candi-
date for the antiapoptotic effects of glucocorticoids (Suzuki et al.,
1998;Asadaet al., 1999) [for review, seeGartel andTyner (2002) and
Coqueret (2003)]. Therefore, in the present study, we tested the hy-
pothesis that corticosterone would protect neurons from apoptosis
via both upregulation and PI3-Akt-kinase-dependent phosphoryla-
tion, activation, and cytoplasmic translocation of p21Waf1/Cip1.
Materials andMethods
Materials. Corticosterone, spironolactone, mifepristone, cycloheximide,
DMSO, and enzyme standard for the kinetic lactate dehydrogenase
(LDH) test were obtained from Sigma (Taufkirchen, Germany);
LY294002 and SH6 were from Merck Biosciences (Bad Soden, Germa-
ny); Neurobasal medium and supplement B27 were from Invitrogen
(Eggenstein, Germany); modified Eagle’s medium, PBS, HEPES buffer,
trypsin/EDTA, penicillin–streptomycin, L-glutamine, collagen-G, and
poly-L-lysine were from Biochrom (Berlin, Germany); multiwell plates
were from Falcon (Franklin Lakes, NJ); rabbit polyclonal antibodies
raised against total p21Waf1/Cip1 (sc-397) or phospho-specific p21 [Thr
145] (sc-20220R), histone deacetylase inhibitor 1 (HDAC1) (sc-7872),
and actin (sc-8432) were from Santa Cruz Biotechnology (Heidelberg,
Germany); antibodies against total caspase-3 [catalog number (Cat. No.)
9662], cleaved caspase-3 (Cat. No. 9662), total Akt (Cat. No. 9272), and
Pi-Akt [Ser 473] (Cat. No. 9271) were from Cell Signaling Technology
(Frankfurt, Germany); mouse anti-microtubule-associated protein 2
(Map-2) antibody was obtained from Millipore (Hofheim, Germany),
secondary anti-rabbit horseradish peroxidase-linked antibody was from
GEHealthcare (Braunschweig, Germany); all other secondary antibodies
[fluorescein isothiocyanate (FITC) or Rhodamine Red-X coupled] were
obtained from Jackson ImmunoResearch (West Grove, PA); enhanced
chemiluminescence kits were from GE Healthcare and Pierce Biotech-
nology (Rockford, IL); x-ray films were from Kodak (Stuttgart, Ger-
many); Hoechst 33258 and high-range molecular-weight standard was
from Sigma. Ethylcholine aziridinium (AF64A) was prepared from acet-
ylethylcholine mustard (Sigma) according to Fisher et al. (1982). Fugene
was obtained from Roche (Grenzach-Wyhlen, Germany).
Primary neuronal cell cultures. Primary neuronal cultures of cerebral
cortex were obtained from embryos [embryonic day 16 (E16) to E18] of
Wistar rats (Bundesinstitut fu¨r gesundheitlichenVerbraucherschutz und
Veterina¨rmedizin, Berlin, Germany) or from mouse embryos from
p21Waf1/Cip1 “knock-out” (p21Waf1/Cip1/) or their corresponding lit-
termates (p21Waf1/Cip1/) obtained from Jax mice (strain B6; 129S2-
Cdkn1a tm1Tyj/J; stock number 003263; The Jackson Laboratory, Bar
Harbor, ME) as described previously (Harms et al., 2000, 2004). Briefly,
cerebral cortices were dissected, incubated for 15 min in trypsin/EDTA
(0.05/0.02% w/v in PBS) at 36.5°C, rinsed twice with PBS and once with
dissociation medium (modified Eagle’s medium with 10% fetal calf se-
rum, 10 mM HEPES, 44 mM glucose, 100 U of penicillin plus streptomy-
cin per milliliter, 2 mM L-glutamine, 100 IE insulin/L), dissociated by
Pasteur pipette in dissociation medium, pelleted by centrifugation
(210 g for 2min at 21°C), redissociated in startermedium (Neurobasal
mediumwith supplement B27, 100 U of penicillin plus streptomycin per
milliliter, 0.5 mM L-glutamine, and 25 M glutamate), and plated out in
24-well or six-well plates at a density of 150,000 or 100,000 (on coverslips
for immunocytochemistry) cells/cm2. Wells were coated with poly-L-
lysine for 1 h at room temperature (0.5% w/v in PBS), rinsed with PBS,
and incubated with coating medium (dissociation medium with 0.03‰
w/v collagen G) for 1 h at 36.5°C with two rinsing steps with PBS. Cells
were seeded in starter medium. Primary cortical neurons were cultivated
with serum-free Neurobasal medium with B27 supplement for 10–14 d
in vitro (DIV) before starting with the experiment. Supplement B27 con-
tained58 nM corticosterone.
Injury paradigm. Serum-free primary neuronal cultures were used af-
ter 9–11 DIV. The condition of cells at various time points after induc-
tion of injury was determined morphologically by phase-contrast mi-
croscopy. The neurotoxin AF64A was added to reach the final
concentration of 40 M and remained in the medium throughout the
observation period of 72 h instead of a 5 h exposure followed by replace-
ment of conditioned medium as described previously (Harms et al.,
2000, 2001). The effect of the toxin was comparable in both procedures.
Controls were exposed an equivalent amount of vehicle.
Staurosporine was dissolved in DMSO (10 mM stock solution) and
diluted with PBS to give the final concentration of 300 nM in culture. The
vehicle-treated cultures received the same amount of DMSO in PBS.
Glutamate exposure was performedwith 100M glutamate for 30min
with subsequent rinsing and reapplication of conditioned medium.
Treatment with corticosterone, spironolactone, mifepristone, LY294002,
and cycloheximide. Corticosterone was dissolved in DMSO (250 mM
stock solution) and added to the cell cultures in a dose range of 1–50 M
(final concentration in the medium) at different time points before and
after the initiation of the injury. Spironolactone was dissolved in DMSO
(50 mM stock solution), and mifepristone was dissolved in DMSO (10
mM stock solution; higher concentrations were not soluble in DMSO)
and diluted in medium. The final concentration in the medium was 10
M.Consequently, corticosteronewas used in equimolar concentrations.
LY294002 was dissolved in DMSO (65 mM stock solution) with 5 M as
final concentration. SH6 was dissolved in DMSO (1 mM stock solution)
with 5 M as final concentration. Cycloheximide, dissolved in medium,
was added to give a final concentration of 500 ng/ml medium. Spirono-
lactone, mifepristone, LY294002, or cycloheximide was added at the
same time point as corticosterone.
Cell death assays. Neuronal injury was quantitatively assessed by the
measurement of LDH in themedium (Koh and Choi, 1987) at 48 or 72 h
after AF64A application or bymeasurement of caspase-3 activity (Harms
et al., 2004). Cell viability was assessed after staining of naive cell cultures
with propidium iodide to distinguish living and dead cells (0.001 mg/ml
for 5min with subsequent rinsing) as described previously (Endres et al.,
2004). Pictures from both phase-contrast images and fluorescent pic-
tures were taken using a digital camera. Pictures weremerged, and viable
and dead neuronal cells were counted and presented as a percentage of
viable neurons of all cells. To assess neurons withmorphological features
of apoptosis with chromatin condensation, nuclear membrane blebbing,
retraction of dendrites, and apoptotic bodies, cultures were subjected to
indirect fluorescence immunocytochemistry against the cytoplasmic
neuronal marker Map-2 (1:500; developed with tetramethylrhodamine
isothiocyanate-conjugated secondary antibody) and aDNA counterstain
with bis-benzimide (Hoechst 33258) as described previously (Harms et
al., 2004). Neurons (200) were counted for each condition, and the num-
ber of healthy neurons was calculated as a percentage of control.
Quantitative real-time reverse transcription-PCR of p21Waf1/Cip1
mRNA. Total cellular RNA from primary cortical neurons was isolated,
and RNA preparation and cDNA synthesis were performed as described
previously. Expression of each sample was normalized for RNA prepara-
tion and reverse transcriptase reaction on the basis of -actin mRNA
content (Ruscher et al., 2002, Prass et al., 2003). For detection of the
amplification products in -actin and p21Waf1/Cip1 reverse
transcription-PCR, we used the LightCycler and FastStart DNA Master
kit (Roche Molecular Biochemicals, Penzberg, Germany), as recom-
mended by the manufacturers. Thermal cycling started with 10 min at
95°C and proceeded with 55 cycles of 95°C for 15 s, 68°C for 10 s, and
72°C for 15 s (amplification product data acquisition at 90°C for p21Waf1/
Cip1 and 86°C for -actin). For amplification and detection, we used the
LightCycler Relative Quantification software (Roche Molecular
Biochemicals). The following sequence-specific primers (Tibmolbiol,
Berlin, Germany) were used: -actin forward (fwd), 5-ACCCA-
CACTGTGCCCATCTA-3; -actin reverse (rev), 5-GCCACAGG-
ATTCCATACCCA-3; p21Waf1/Cip1 fwd, 5-AGAGTGCAAGAC-
AGCGACAAGG-3; and p21Waf1/Cip1 rev, 5-GGTGATGTCCGACC-
TGTTCCG-3.
Immunoblots. Immunoblots were performed as described previously
(Katchanov et al., 2001). NP-40 buffer was used for whole cellular ex-
tracts of cortical neuron (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 0.5%
NP-40, 5mM EDTA, pH 8.0, 1mM phenylmethylsulfonylfluoride, 20mM
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NaF, 1 mM Na3VO4, and protease inhibitor mixture; Roche). Samples
containing 30g of protein or the equivalent of 25,000 cells in lysis buffer
were subjected to SDS-PAGE (4–20% gradient Precise Protein Gels;
Pierce Biotechnology) and immunoblotting procedure. Primary anti-
bodies were used in a concentration of 0.2 g/ml overnight at 4°C on a
platform with gentle agitation, and horseradish peroxidase-linked sec-
ondary antibodies were used at 1:5000 for 1 h at room temperature.
Detection was performed using the enhanced chemiluminescence assay
(GE Healthcare).
Cellular fractionation. Cellular fractionation was performed 24 h after
exposure toAF64Ausing ice-cold cell lysis buffer (10mMHEPES, pH7.5,
2 mMMgCl2, 1 mM EDTA, 1 mM EGTA, 10 mM KCl, 10 mMNaF, and 0.1
mM Na3VO4 with one tablet of protease inhibitor mixture per 25 ml of
buffer and freshly added 1 mM DTT) to harvest cells using a cell scraper
and 100 l of buffer per six wells. For each condition, six wells were
pooled. Cells were incubated for 15 min on ice, and 10 l of 10% NP-40
was added followed by centrifugation for 1min at 13,000 rpm at 4°C. The
supernatant was taken as the cytoplasmic fraction. The pellet was washed
twice using cell lysis buffer, and 15l of nuclear extraction buffer perwell
was added (25 mM HEPES, pH 7.5, 500 mM NaCl, 10 mM NaF, 10%
glycerol, 0.2% NP-40, 5 mM MgCl2, and freshly added protease inhibi-
tors and 1 mM DTT) followed by sonification and centrifugation at
13,000 rpm for 5min. The supernatant was taken as the nuclear fraction.
Protein content was determined, and equal loading and fractionation
were evaluated using antibodies raised against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) fromMillipore, MAB374 as a cyto-
plasmic marker, and HDAC1 (sc-7872; Santa Cruz Biotechnology) as a
nuclear marker.
Immunocytochemistry. For immunocytochemical analysis of cell cul-
tures, cells were seeded onto glass coverslips at a density of 100,000 cells/
cm2, fixed with 3.7% formaldehyde in PBS for 8.5 min, permeabilized
with 0.1% Triton X-100 in PBS (8.5 min), and exposed to blocking
solution (PBS containing 5% goat serum and 0.2% Tween 20) for 1 h at
room temperature. Cultures were then incubated with primary antibod-
ies and developed with Rhodamine Red-X- or FITC-labeled secondary
antibody. Hoechst dye was used for genomic DNA counterstain. Control
slides were treated the same way except that primary antibodies were
omitted, resulting in no visible staining.
Confocal pictures and three-dimensional rendering of confocal images.
Confocal pictures and three-dimensional rendering of confocal images
were performedwith Velocity imaging software (Improvision, Coventry,
UK). All confocal microscopy was performed using a spectral confocal
microscope (TCS SP2; Leica, Nussloch, Germany). Appropriate gain and
black level settings were determined on control slides stained with sec-
ondary antibodies alone. Colocalization images were processed with
Photoshop version 6.0 (Adobe Systems, San Jose, CA).
Antisense transfections. The following synthetic HPLC-purified oli-
godeoxynucleotides (BioTez, Berlin-Buch, Germany) were used to de-
crease expression of rat p21Waf1/Cip1 (GenBank U24174): 5-
GGCAGGCGCCGATCCACAGCG-3 (sense), 5-CGCTGTGGAT
CGGCGCCTGCC-3 (antisense). These sequences were not significantly
homologous to genes other than rat p21 by BLAST (basic local alignment
search tool) search (National Center for Biotechnology Information).
Cortical neurons were seeded on glass coverslips at a density of 150,000
cells/cm2 and transfected with p21 sense or antisense oligonucleotides or
fugene (Roche) alone on DIV 9 24 h before pretreatment with 50 M
corticosterone. Optimal conditions for transfection were achieved ac-
cording to themanufacturer’s instructions. Briefly, 1l of distilled water
containing 1 g of oligodeoxynucleotides and 2 l of fugene were incu-
bated separately in 20 l of OptiMEM for 20 min, incubated for an
additional 30 min before addition of 300 l of Neurobasal medium, and
added to a 24-well plate with cortical neurons. Themediumwas replaced
after 6 h with Neurobasal medium from sister cultures. Cells were fixed
with paraformaldehyde 48 h after AF64A, and immunocytochemistry
was performed with antibodies against p21Waf1/Cip1 (green) to demon-
strate endogenous levels of p21Waf1/Cip1 or Map-2 (red) to reveal neuro-
nal origin. “Knock-down” efficiency was determined by endogenous lev-
els of p21Waf1/Cip1 and cell counts. Sister cultures were treated with
fugene alone. Nuclear morphology was revealed by Hoechst staining. A
total of 200 Map-2-positive neurons from five high-power fields taken
from three different slides per group were evaluated as viable/healthy or
dead/severely damaged and presented as a percentage of all Map-2-
positive neurons. Experiments were performed in triplicate.
Recombinant adenoviral constructs and transfections. Ad-p21Waf1/Cip1
and Ad--galactosidase (-Gal) were used as described previously
(Hauck et al., 2002). Virus propagation and purification were performed
as described previously (von Harsdorf et al., 1999). At 24 h after adeno-
viral infection (100 plaque-forming units/cell) cortical neurons were ex-
posed to AF64A for 48 h. The expression and nuclear localization of
ectopically expressed proteins were confirmed by fluorescence micros-
copy of fixed cells using immunostaining with specific antibodies (data
not shown).
Results
Corticosterone protects neurons from apoptosis via
activation of the PI3-Akt-kinase pathway
Differentiated rat primary cortical neurons were exposed to
AF64A, leading to full cell disintegration by 48–72 h. As reported
previously, neuronal cells react to AF64Awith a delayed, caspase-
dependent apoptotic cell death. The caspase dependence has
been proven both by the broad-spectrum caspase inhibitor
Z-VAD-FMK and the caspase-3-specific inhibitor Z-DQMD-
FMK (Harms et al., 2000, 2004). The apoptotic cell death has
been confirmed previously byDNA laddering,-fodrin cleavage,
terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labeling, Hoechst 33258 staining, andmorpholog-
ical appearance in phase-contrast microscopy (Harms et al.,
2000, 2001, 2004; Lautenschlager et al., 2000). Release of LDH
into the culture medium served as an indirect marker of cell
death. Pretreatment with high-dose corticosterone (1–50 M)
protected cortical neurons in a time- and dose-dependent man-
ner from AF64A and also completely reduced activation and
cleavage of caspase-3 (maximum protection achieved with 20 h
pretreatment) (see supplemental Table 1, available at www.
jneurosci.org as supplemental material; Fig. 1A,C,F). Cotreat-
ment with antagonists of either glucocorticoid or mineralocorti-
coid receptor subtypes at concentrations equimolar to that of
corticosterone completely bypassed the neuroprotective effect of
corticosterone (Fig. 1B). Pretreatment of receptor antagonist
without corticosterone did not alter AF64A toxicity significantly
(data not shown).
The neuroprotective effect of corticosterone (50 M) was
tested in two additional models of neurodegeneration, including
exposure to staurosporine or glutamate. A significant decrease in
LDH release was achieved 24 and 48 h after staurosporine. After
glutamate exposure, the acute excitotoxic damage at 24 and 48 h
was not antagonized by corticosterone, whereas the late increase
between 48 and 72 h was prevented (supplemental Table 2, avail-
able at www.jneurosci.org as supplemental material).
To test whether the protective effect of corticosterone was
mediated via the PI3-Akt-kinase-pathway, we coadministered ei-
ther the PI3-kinase inhibitor LY294002 or the Akt-kinase inhib-
itor SH6. Both inhibitors completely reversed the neuroprotec-
tive effect of corticosterone (Fig. 1D). Moreover, corticosterone
treatment induced transient (i.e., 30–180 min, maximum after
90 min) phosphorylation of Akt-kinase at serine 473, which was
completely blocked by SH6 (Fig. 1E). This increase in phosphor-
ylation was not associated with an increase in total Akt expres-
sion. Together, these results demonstrate that corticosterone
protects fromAF64A-induced apoptosis via activation of the PI3-
Akt-kinase pathway.
4564 • J. Neurosci., April 25, 2007 • 27(17):4562–4571 Harms et al. • Neuroprotection by Glucocorticoids; Role of p21
Corticosterone confers enhanced
phosphorylation and cytoplasmic
appearance of p21Waf1/Cip1
via Akt-kinase
The cell cycle inhibitor p21Waf1/Cip1 has an
Akt-kinase-specific phosphorylation site
at threonine 145 (Zhou et al., 2001). Using
an antibody directed against the p21-Thr
145 phosphorylation, we tested whether
corticosterone (via Akt-kinase) would
confer phosphorylation and increase the
cytoplasmic appearance of phosphory-
lated p21Waf1/Cip1 (Pi-p21). Confocal im-
ages, including multiple z-plane images
and three-dimensional reconstruction
demonstrated that Pi-p21 [Thr 145] was
present at low levels in the nucleus of naive
Figure 1. Corticosterone protects neurons from apoptosis via activation of the PI3-Akt-kinase pathway. A, Cortical neurons
werepretreated (20h1h)with corticosterone (Cort.), before additionofAF64A (40M). LDH release into themediumwasused
as a marker of cellular disintegrity. Data are presented as increase in LDH release above the baseline (108.7 2.3 at 48 h; mean
values SEM; n 24–88 wells; data pooled from 2–6 experiments). Treatment of naive cells with Cort. did not significantly
4
change basal LDH release (124.5 2.2 U/mlmedium); *p
0.001 versus AF64A; one-way ANOVA followed by Tukey’s
post hoc test. B, Receptor antagonists reverse the neuropro-
tective effect of Cort. Cortical neurons were pretreated with
the glucocorticoid receptor antagonist mifepristone (10M)
30 min before corticosterone (10 M) or the mineralocorti-
coid receptor antagonist spironolactone (50M) 30 min be-
fore corticosterone (50M). In naive cells, the basal LDH re-
lease at 72 h (41.4 1.4)was not affected by treatmentwith
mifepristone or Cort. plus mifepristone (35.7  2.6 and
48.7 3.0). Basal release of LDH (35.5 2.7) also did not
change in the presence of spironolactone or Cort. plus spi-
ronolactone (34.8  0.6 and 46.7  2.5 U/ml medium);
*p 0.05 versus AF64A; #p 0.001 versus corresponding
AF64A plus Cort. (10 or 50M); one-way ANOVA followed by
Tukey’s post hoc test (n 16). C, Cortical neurons were pre-
treated with the Akt-specific inhibitor SH6 (5 M) 21 h and
Cort. (50M) 20 h before addition of AF64A. Cells were har-
vestedat the indicated timepoints afterAF64A treatmentand
subjected to Western blot analysis. Membranes were probed
with antibodies raised against total caspase-3 and performed
in duplicate. D, Cortical neurons were treated with the PI3-
kinase inhibitor LY294002 (5M) or the Akt-kinase inhibitor
SH6 (5M) 21 h and/or Cort. (50M) 20 h before AF64A (40
M) was added. LDH release is presented as increase in LDH
release above basal levels (71.3 4.8) at 48 h after addition
of AF64A. Treatment of naive cells with Cort. or Cort. plus
LY294002 did not change basal LDH release (64.9 5.8 and
67.0  7.8, respectively), nor did SH6 or SH6 plus Cort.
(65.83.3 and69.45.1U/mlmedium);n12–23wells
pooled from two representative independent experiments.
*p 0.001 versus control cultures; #p 0.001 versus AF64A
plus Cort.; one-way ANOVA followed by Tukey’s post hoc test.
E, Cortical neurons were treated with Cort. (50 M) or Cort.
(50M) plus SH6 (5M; 1 h pretreatment). Cells were har-
vested at the indicated time points after Cort., and samples
were analyzed by immunoblot procedure. Membranes were
incubatedwith antibodies raised against Pi-Akt [Ser 473] and
total Akt. A representative blot of three independent experi-
ments is shown. F, Cortical neurons were pretreated with
Cort. (50M; 20 h) before AF64A (40M) and harvested at
24 h after AF64A. Caspase-3 activity was measured as de-
scribedpreviously (Harmset al., 2004).n5–6wells pooled
from two independent experiments. *p 0.039 versus con-
trol cultures; #p 0.046 versus AF64A; one-way ANOVA fol-
lowed by Tukey’s post hoc test. AMC, 7-Amino-4-
methylcoumarin.
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Map-2-stained neurons but was hardly
visible in the cytoplasm (Fig. 2A,B). After
treatment with corticosterone, Pi-p21
[Thr 145] was upregulated and expressed
in both nucleus and cytoplasm, which was
completely reversed by cotreatment with
SH6 (Fig. 2C). Treatment with AF64A re-
sulted in a profound downregulation of
Pi-p21 [Thr 145] in untreated but not in
corticosterone-treated neurons (Fig. 2A).
Immunoblotting showed an increase of
Pi-p21 [Thr 145] 1 h after corticosterone
treatment, whereas total p21Waf1/Cip1 re-
mained unaffected (Fig. 2C). After AF64A,
both total p21Waf1/Cip1 and Pi-p21 [Thr
145] levels markedly declined, which was
prevented in the presence of corticoste-
rone. In contrast, cotreatment with the
Akt-kinase inhibitor SH6 resulted in a
time-dependent marked loss of both total
and Thr 145-phosphorylated p21Waf1/Cip1
(Fig. 2C). For further identification of the
cellular localization of Pi-p21, we per-
formed fractionation of nucleus and cy-
tosol followed by Western blot analysis of
Pi-p21. Under control conditions, Pi-p21
was exclusively detectable in the nucleus
fraction, whereas after treatmentwith cor-
ticosterone, Pi-p21 was distributed both
in the nucleus and cytosol. After AF64A
treatment, Pi-p21 almost completely dis-
appeared in the nucleus and was not de-
tectable in the cytosol. After pretreatment
with corticosterone, the AF64A-induced
loss of Pi-p21 was partly prevented and
Pi-p21 appeared in the cytosol. Moreover,
in the presence of SH6, Pi-p21 was almost
not detectable in the nuclear fraction
under basal conditions, and the cortico-
sterone-induced increase in the cytosol
was completely prevented (Fig. 2D). To-
gether, these results indicate that cortico-
sterone induces phosphorylation at T145,
and cytoplasmic shuttling of p21Waf1/Cip1
is mediated by Akt-kinase. Interestingly,
phosphorylation of Akt-kinase was a tran-
sient event with amaximum at 60–90min
after addition of corticosterone (Fig. 1E),
whereas increased cytoplasmic and nu-
clear expression of Pi-p21 [Thr 145] was
still evident 44 h after corticosterone
(Fig. 2A,B).
Corticosterone induces
p21Waf1/Cip1-gene transcription
The p21Waf1/Cip1 promoter region con-
tains a glucocorticoid receptor response
region. Therefore, we tested whether, in
addition to increased phosphorylation,
corticosterone treatment would increase
p21Waf1/Cip1 gene and protein expression.
Real-timePCR, immunoblots, and immu-
nocytochemistry demonstrated that corti-
Figure 2. Cytoplasmic appearance of p21Waf1/Cip1 and Pi-p21 [Thr 145] phosphorylation after corticosterone is inhibited by
Akt-kinase inhibition with SH6. A, Cortical neurons immobilized on microscope glass coverslips were pretreated with the Akt
inhibitor SH6 (21 h) and/or 50M corticosterone (Cort.; 20 h) before AF64A was added. Cells were fixed 24 h after addition of
AF64A, and immunocytochemistry with antibodies raised against the phosphorylated form of p21Waf1/Cip1 (Pi-p21 [Thr 145];
green) or neuronalMap-2 expression (red)was performed. Imageswere takenwith a confocalmicroscope.B, The two top images
represent confocal Z-series along the y–z-axis (right narrow panel) and the x–z-axis (bottom narrow panels) through the somata
ofMap-2-positive cells. Control cultures (left) revealed nuclear localization of Pi-p21 [Thr 145],whereas after treatmentwith Cort.
(right), cytoplasmic localization was observed (respective green insets at higher magnification). This pattern of localization of
Pi-p21 [Thr 145] is also visible in the three-dimensional reconstructions (bottom). Scale bars: A, B, 30m. Inset in B, twofold
magnification. C, Cortical neuronswere pretreatedwith SH6 and/or 50MCort. before AF64Awas added. Cellswere harvested 1h
after treatment with corticosterone or 24 h after treatment with AF64A and subjected to SDS-PAGE and immunoblotting. Mem-
branes were probed with a rabbit polyclonal antibody against p21Waf1/Cip1, Pi-p21 [Thr 145], and actin to demonstrate equal
loading. Three to six independent experiments were performed. Densitometric quantification of the blots revealed an increase in
the p21/actin ratio from0.345 0.051 in control cultures to 0.582 0.078 in Cort.-treated cells (n 6; p 0.05). Similarly, the
Pi-p21/actin ratio significantly increased from 0.150 0.015 in control cultures to 0.373 0.090 44 h after Cort. (n 3; p
0.05). The Cort.-induced increase in both proteins was withheld by cotreatment with SH6 (0.353 0.039 and 0.083 0.020,
respectively).D, Cortical neurons were pretreated with SH6 (1 h before Cort.) and/or 50M Cort. (20 h) before AF64Awas added.
Cells were harvested 44 h after treatmentwith Cort. or 24 h after treatmentwith AF64A and subjected to cellular fractionation. To
confirm successful separation of the compartments, HDAC1 and GAPDH were used as indicators for the nuclear and cytoplasmic
fraction. Pi-p21 [Thr 145] signalwasdetected in cultures treatedwithorwithout theAkt kinase inhibitor SH6. Exposure timeswere
kept constant during visualization. Two independent experiments were performed.
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costerone dose- and time-dependently induced p21Waf1/Cip1
mRNA synthesis and protein expression (Fig. 3A–D). In the
physiological range (0.1 M), corticosterone did not affect the
level of p21Waf1/Cip1 mRNA. However, in the dose range of 1–50
M corticosterone, the mRNA levels dose-dependently increased
24 h after treatment, correlating well with the neuroprotective
potency of corticosterone (Fig. 1A). The increase in p21Waf1/Cip1
mRNA was completely abolished by cotreatment with antago-
nists of either glucocorticoid or mineralocorticoid receptor sub-
types (Fig. 3B). Moreover, inhibition of Akt-kinase by SH6 not
only reversed the corticosterone-induced increase in p21Waf1/Cip1
mRNA, but even decreased its level under basal conditions (Fig.
3C). Similar to the findings with Pi-p21 [Thr 145] immunocyto-
chemistry, p21Waf1/Cip1 was mainly present in the nucleus of na-
ive neurons but was found in both nucleus and cytoplasm of
corticosterone-treated neurons. AF64A conferred a profound
lossofp21Waf1/Cip1,whichwaspreventedby corticosteronepretreat-
ment (Fig. 4A,B). The protein synthesis inhibitor cycloheximide
completely blocked the neuroprotective effects of corticosterone
(Fig. 4C), which suggests that upregulation of p21Waf1/Cip1 expres-
sion (possibly along with other proteins) is necessary for
corticosterone-mediated neuroprotection.
An alternative explanation for the neuroprotective effects of
corticosterone would be inhibition of cdk activity, because nu-
clear p21Waf1/Cip1 inhibits cdk2. Indeed, AF64A significantly ac-
tivated cdk2 (see also Katchanov et al., 2001); cotreatment with
corticosterone, however, did not inhibit cdk2 activation induced
by AF64A as shown in a preliminary study (data not shown).
p21Waf1/Cip1 is essential for the neuroprotective effect
of corticosterone
To test whether p21Waf1/Cip1 is essential for the neuroprotective
effect of corticosterone, we transfected neurons with antisense
deoxynucleotide to reduce the amount of p21Waf1/Cip1 (Fig.
5A,B). Successful knock-down of p21Waf1/Cip1 protein expres-
sion was confirmed by immunostaining of fixed cells (Fig. 5B).
Transfection with p21Waf1/Cip1 antisense oligonucleotides, but
not with sense oligonucleotides, abrogated the neuroprotective
action of corticosterone as assessed by cell counts of viable Map-
2-positive neurons (Fig. 5A).
In addition, we prepared primary cortical neurons frommice
deficient in p21Waf1/Cip1 gene expression (p21Waf1/Cip1 knock-out
mice) alongwithwild-type littermates, which showed no obvious
Figure 3. Transcriptional activation of p21Waf1/Cip1 expression is blocked by glucocorticoid
receptor antagonists and the Akt-kinase inhibitor SH6.A, Cortical neuronswere treatedwith 50
M Cort., and cells were harvested at the indicated time points. Real time-PCR for p21Waf1/Cip1
mRNAwas performed from two independent samples in duplicate and compared with actin as
4
a housekeeping protein. Data are shown as fold induction SEM; *p 0.001 versus control
cultures; one-wayANOVA followedby Tukey’spost hoc test.B, Receptor antagonists reverse the
transcriptional activation of p21Waf1/Cip1. Cortical neurons were pretreated with the glucocor-
ticoid receptor antagonist mifepristone (10M) 30 min before corticosterone (10M) or the
mineralocorticoid receptor antagonist spironolactone (50M) 30minbefore corticosterone (50
M), and cells were harvested 24 h after application of corticosterone. Real time-PCR for
p21Waf1/Cip1mRNAwasperformed from three independent samples in duplicate and compared
with actin as a housekeeping protein. Data are shown as fold induction SEM; *p 0.001
versus control cultures; #p 0.001 versus corresponding Cort. dose plus vehiclewithout recep-
tor antagonist; *one-way ANOVA followed by Tukey’s post hoc test. C, Cortical neurons were
treated with the indicated concentration of Cort. or 5M SH6, and cells were harvested after
24 h. Real time-PCR for p21Waf1/Cip1 mRNA was performed from two independent samples in
duplicate and compared with actin as a housekeeping protein. Data are shown as fold induc-
tion SEM; *p 0.001 versus control cultures; one-way ANOVA followed by Tukey’s post hoc
test; #p 0.032 versus vehicle;p 0.001 versus Cort. plus vehicle.D, Cortical neurons with
the indicated concentrations of corticosterone and harvested 24 h later and subjected to SDS-
PAGE.Membraneswere incubatedwith either antibodies raised against Pi-p21 [Thr 145] or p21
or GAPDH as a housekeeping protein. A representative blot from two independent experiments
is shown. AU, Arbitrary units.
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differences in cellular viability at baseline
or after AF64A (as determined by LDH,
phase-contrast morphology, and pro-
pidium iodide staining). Corticosterone
pretreatment provided significant protec-
tion in wild-type neurons; however, it did
not protect p21Waf1/Cip1 knock-out neu-
rons at all (Fig. 5C–E). Similarly, the pro-
tection achieved by corticosterone against
staurosporine- or glutamate-induced
neuronal damage was not detectable in
p21Waf1/Cip1 knock-out neurons (supple-
mental Table 3, available at www.
jneurosci.org as supplemental material).
Together, these experiments demonstrate
that p21Waf1/Cip1 is essential for the neuro-
protective effects of corticosterone.
Ectopic expression of p21Waf1/Cip1
confers neuroprotection
Next, we tested whether ectopic expres-
sion of p21Waf1/Cip1 by adenovirus deliv-
ery would protect neurons from AF64A.
Transduction efficiency was close to
100%, as determined by -galactosidase
staining and colocalization with Map-2
(data not shown). Adenovirally delivered
p21Waf1/Cip1 protected neurons from
AF64A-induced cell death to a degree sim-
ilar to corticosterone. Cotreatment of cor-
ticosterone plus adenoviral delivery of
p21Waf1/Cip1 conferred a small but signifi-
cant additional protective effect compared
with p21Waf1/Cip1 or corticosterone alone
(Fig. 6A,B). Interestingly, in these neu-
rons, retraction of dendrites and nuclear
membrane blebbing in response to AF64A
were also inhibited (Fig. 6A).
Discussion
Our study has the following major findings: (1) high-dose corti-
costerone protects primary cortical neurons from apoptotic cell
death induced by the neurotoxin AF64A in vitro, and this appears
to involve both glucocorticoid and mineralocorticoid receptor
signaling. Neuroprotection by corticosterone could also be dem-
onstrated in staurosporine-induced apoptosis and in the delayed
cell death after glutamate exposure. (2) Neuroprotection by cor-
ticosterone is dependent on the activation of both PI3-kinase and
Akt-kinase. (3) Via PI3-Akt-kinase activation, corticosterone
mediates phosphorylation at Thr 145 and cytoplasmic appear-
ance of the cdk inhibitor p21Waf1/Cip1. In addition, corticosterone
dose-dependently increases total p21Waf1/Cip1 gene and protein
expression. (4) Inhibition of Akt-kinase-dependent phosphory-
lation and subsequent cytoplasmic appearance of Pi-p21 com-
pletely blocks the neuroprotective effect of corticosterone. (5)
p21Waf1/Cip1 is essential for neuroprotection by glucocorticoids,
because corticosterone did not protect neurons at all from dam-
age induced by AF64A, staurosporine, or glutamate, when
p21Waf1/Cip1 gene expression was abolished either by oligonucle-
otide treatment or gene deletion. (6) Last, ectopic expression of
p21Waf1/Cip1 provides neuroprotection independent of (but sim-
ilar to) corticosterone treatment. Together, this study identifies
p21Waf1/Cip1 as a novel antiapoptotic therapeutic target in post-
mitotic neurons and demonstrates that it serves as the molecular
mechanism of neuroprotection by high-dose glucocorticoids.
Activation of PI3-Akt-kinase is required for the
neuroprotective effects of corticosterone
PI3-Akt-kinase activation is necessary for the antiapoptotic ef-
fects of corticosterone. Neuroprotection was completely abol-
ished by LY294002, an inhibitor of PI3 kinase, and by SH6, an
Akt-kinase inhibitor. Akt-kinase became active as early as 30min
after corticosterone treatment. Indeed, rapid, nongenomic ef-
fects of high-dose glucocorticoid treatments have been described
in non-neuronal cells. For example, nontranscriptional activa-
tion of endothelial nitric oxide synthase in endothelial cells by
high-dose glucocorticoids confers acute cardioprotective effects,
and this is mediated via the glucocorticoid receptor and PI3-Akt-
kinase (Hafezi-Moghadam et al., 2002). Surprisingly, then, in our
studymaximal neuroprotection was achieved only after 20 h cor-
ticosterone pretreatment. This and the fact that neuroprotection
was abolished by the protein synthesis inhibitor cycloheximide
indicate that (in addition to PI3-Akt-kinase activation) synthesis
of new proteins is necessary for corticosterone-induced neuro-
protection. The potential of our evidence for the involvement of
PI3-Akt-kinase in neuroprotection is limited, however, because
most of the results refer to the use of SH6 only.
Figure 4. p21Waf1/Cip1 loss after neuronal apoptosis is reversed by corticosterone.A, Cortical neuronswere treatedwith 50M
corticosterone (Cort.) and 20 h later with AF64A. Fixed cells were subjected to immunocytochemistry using anti-p21Waf1/Cip1
(green) andMap-2 (red). Scale bar, 30m.B, Cortical neuronswerepretreatedwith 50MCort. (20h) andAF64A, harvested, and
subjected to SDS-PAGE and protein blotting at the indicated time points after AF64A. Membranes were probed with a rabbit
polyclonal antibody against p21Waf1/Cip1 and actin as a loading control. Densitometric quantification of the blots revealed an
increase in thep21/actin ratio from0.2480.068 in control cultures to0.4220.056 inCort.-treated cells after 32h (n2;p
0.05). AF64A induced a time-dependent loss of p21 protein levels, which was statistically significant after 24 h (control, 0.391
0.061; AF64A, 0.2410.071) andwas abolishedbypretreatmentwith Cort (0.4510.065;p0.05;n3).C, Cortical neurons
were treated with Cort. (50M) and/or cycloheximide (Chx; 1 h preincubation) before AF64A was applied. LDH release into the
supernatant was measured after 72 h. The basal LDH release at 72 h was 142.1 2.5; after treatment with Cort. alone, it was
152.8 5.7; with Chx alone, 76.6 6.0; and with Cort plus Chx, 93.5 2.5 U/ml medium. The increase in LDH release was
calculated from the corresponding control. *p 0.001 versus AF64A plus Cort.; #p 0.001 versus AF64A alone; one-way ANOVA
followed by Tukey’s post hoc test. n 12–23 pooled from two independent experiments.
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p21Waf1/Cip1 as a novel antiapoptotic
target of glucocorticoids
Corticosterone induced phosphorylation
of p21Waf1/Cip1 at Thr 145 and subsequent
cytoplasmic appearance of Pi-p21, which
could be completely blocked by Akt-
kinase inhibition. Although phosphoryla-
tion of Akt-kinase was transient, increased
levels of Pi-p21 [Thr 145] and its cytoplas-
mic translocation persisted over time. In-
deed, in non-neuronal cells, p21Waf1/Cip1
after phosphorylation and cytoplasmic
shuttling exerts antiapoptotic effects (Por-
ter, 1999; Zhou et al., 2001; Li et al., 2005).
Moreover, corticosterone induced a
dose-, glucocorticoid and mineralocorti-
coid receptor-, and Akt-kinase-dependent
upregulation of p21Waf1/Cip1 gene and
protein expression in postmitotic neu-
rons. An upregulation of p21Waf1/Cip1 has
previously been demonstrated in prolifer-
ating cells only (Corroyer et al., 1997; Ra-
malingam et al., 1997; Cha et al., 1998;
Cram et al., 1998; Terada et al., 2001). Akt-
kinase controls p21Waf1/Cip1 at both the
transcriptional and posttranslational levels
(Ro¨ssig et al., 2002; Maddika et al., 2007).
Our finding that the corticosterone-induced
increase inp21Waf1/Cip1mRNAwas reversed
both by receptor antagonism and Akt-
kinase inhibition indicates a cooperative in-
teraction of both systems at the p21Waf1/Cip1
gene.
Corticosterone also prevented the dra-
matic loss of p21Waf1/Cip1 after AF64Apre-
ceding neuronal apoptosis. Activation of
cdks and cell cycle reentry has been iden-
tified as a pathway for neuronal apoptosis
[for review, see Becker and Bonni (2004)
and Greene et al. (2004)]. Nuclear
p21Waf1/Cip1 acts as a cdk2 inhibitor;
hence, upregulation of p21Waf1/Cip1 by
corticosterone would provide an attrac-
tive mechanism of action for the neuro-
protective effects of glucocorticoids.
However, our results indicate that cortico-
sterone treatment did not result in a de-
cline of cdk2 activation induced by AF64A
as shown in a preliminary study.
p21Waf1/Cip1 is essential/required for
corticosterone-mediated neuroprotection:
the neuroprotective effect of corticosterone
was abolished when neurons were trans-
fected with p21Waf1/Cip1 antisense oligonu-
cleotides and also in neurons obtained from
p21Waf1/Cip1/ mice. Moreover, ectopic
expression of p21Waf1/Cip1 provided neuro-
protection that was comparable with that of
corticosterone. Together, these results indi-
cate that upregulation, phosphorylation of
p21Waf1/Cip1, and cytoplasmic appearanceof
Pi-p21 are essential for neuroprotection
mediated by corticosterone.
Figure 5. Functional inhibition of p21Waf1/Cip1 reverses the neuroprotective effect of corticosterone. A, Cortical neurons were
transiently transfected with rat p21 antisense and sense oligonucleotides 24 h before pretreatment with 50M corticosterone
(Cort.). Immunocytochemistrywasperformedwith antibodies against p21 (green) orMap-2 (red). Transfectionof either antisense
or sense oligodeoxynucleotide did not influence the viability of control cultures. Nuclear morphology was assessed by Hoechst
staining, and cell counts were performed as described inMaterials andMethods.B, Immunocytochemical analysis of p21Waf1/Cip1
expression shows amarked loss of p21Waf1/Cip1 in AF64A- and Cort. (50M)-treated neurons after transfectionwith p21 antisense
oligonucleotide with subsequent failure of the neuroprotective effect of corticosterone. Transfection with antisense oligode-
oxynucleotide revealed neurons with pronounced (filled arrow), moderate (arrowhead), or weak (open arrow) effects on endog-
enous p21 levels after antisense transfection. Scale bar, 30m. C, Primary cortical neurons derived from p21Waf1/Cip1/ or
p21Waf1/Cip1/micewere treatedwith 10MCort. and 20h laterwithAF64A. LDH release into the supernatantwasmeasured
after 72 h. #p 0.001 versus corresponding control; *p 0.001 versus AF64A plus Cort. in p21Waf1/Cip1/ cultures; p
0.001 versus AF64A in p21Waf1/Cip1/ cultures.D, Naive cellswere incubatedwith propidium iodide (PI; 48 h after AF64A), and
digital imageswere takenwith inverse fluorescence or phase contrast. Viable neuronswere counted and shownas a percentage of
all neurons as described inMaterials andMethods. #p 0.001 versus corresponding control; *p 0.001 versus AF64A plus Cort.
inp21Waf1/Cip1/ cultures; p0.001versusAF64A inp21Waf1/Cip1/ cultures.E, Representativepictures inphasecontrastand
red fluorescent PIweremergedand shown fromcortical neurons derived fromp21Waf1/Cip1/ andp21Waf1/Cip1/mice. Neurons
were treatedwith Cort. (10M) and 20h laterwithAF64A. PI stainingwas performed48h later. Scale bar, 30m.
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Corticosterone inhibits cleavage
of caspase-3
The inhibition of caspase-3 cleavage ap-
pears to play a prominent role in neuro-
protection mediated by corticosterone.
Cytoplasmic p21Waf1/Cip1 may directly in-
activate caspase-3 by forming a complex
with procaspase-3 in mitochondria that is
dependent on phosphorylation (Suzuki et
al., 1998, 1999a,b, 2000). Indeed, cortico-
sterone significantly reduced caspase-3
cleavage and enzymatic activity after
AF64A, which was antagonized by Akt-
kinase inhibition (Fig. 1).
In conclusion, we identify p21Waf1/Cip1
as themolecularmediator of neuroprotec-
tion by glucocorticoids in primary cortical
neurons. High-dose corticosterone con-
fers phosphorylation and possibly cyto-
plasmic translocation of Pi-p21 via PI3-
Akt-kinase signaling as well as
upregulation of p21Waf1/Cip1 gene and
protein expression. p21Waf1/Cip1 emerges
as a novel molecular target for the treat-
ment of neurodegenerative diseases.
References
A´braha´m IM, Harkany T, Horvath KM, Luiten
PGM (2001) Action of glucocorticoids on
survival of nerve cells: promoting neurode-
generation or neuroprotection? J Neuroendo-
crinol 13:749–760.
Amsterdam A, Tajima K, Sasson R (2002) Cell-
specific regulation of apoptosis by glucocorti-
coids. Biochem Pharmacol 64:843–850.
Asada M, Yamada T, Ichijo H, Delia D, Miyazono
K, Fukumuro K, Mizutani S (1999) Apopto-
sis inhibitory activity of cytoplasmic
p21(Cip1/WAF1) in monocytic differentia-
tion. EMBO J 18:1223–1234.
Bailly-Maitre B, de Sousa G, Boulukos K, Gugen-
heim J, Rahmani R (2001) Dexamethasone
inhibits spontaneous apoptosis in primary cultures of human and rat
hepatocytes via Bcl-2 and Bcl-xL induction. Cell Death Differ 8:279–288.
Becker EB, Bonni A (2004) Cell cycle regulation of neuronal apoptosis in
development and disease. Prog Neurobiol 72:1–25.
Behl C, Lezoualc’h F, Trapp T, WidmannM, Skutella T, Holsboer F (1997a)
Glucocorticoids enhance oxidative stress-induced cell death in hip-
pocampal neurons in vitro. Endocrinology 138:101–106.
Behl C, Trapp T, Skutella T, Holsboer F (1997b) Protection against oxida-
tive stress-induced neuronal cell death—a novel role for RU486. Eur
J Neurosci 9:912–920.
Cha HH, Cram EJ, Wang EC, Huang AJ, Kasler HG, Firestone GL (1998)
Glucocorticoids stimulate p21 gene expression by targetingmultiple tran-
scriptional elements within a steroid responsive region of the p21waf1/
cip1 promoter in rat hepatoma cells. J Biol Chem 273:1998–2007.
Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a func-
tion for each cell compartment? Trends Cell Biol 3:65–70.
Corroyer S, Nabeyrat E, Clement A (1997) Involvement of the cell cycle
inhibitor CIP1/WAF1 in lung alveolar epithelial cell growth arrest in-
duced by glucocorticoids. Endocrinology 138:3677–3685.
Cram EJ, Ramos RA, Wang EC, Cha HH, Nishio Y, Firestone GL (1998)
Role of the CCAAT/enhancer binding protein-alpha transcription factor
in the glucocorticoid stimulation of p21waf1/cip1 gene promoter activity
in growth-arrested rat hepatoma cells. J Biol Chem 273:2008–2014.
Endres M, Biniszkiewicz D, Sobol RW, Harms C, Ahmadi M, Katchanov J,
Mergenthaler P, Dirnagl U, Wilson SH, Meisel A, Jaenisch R (2004) In-
creased postischemic brain injury in mice deficient in uracil-DNA glyco-
sylase. J Clin Invest 113:1711–1721.
Evans-Storms RB, Cidlowski JA (2000) Delineation of an antiapoptotic ac-
tion of glucocorticoids in hepatoma cells: the role of nuclear factor-
kappaB. Endocrinology 141:1854–1862.
Fisher A, Mantione CR, Abraham DJ, Hanin I (1982) Long-term central
cholinergic hypofunction induced in mice by ethylcholine aziridinium
ion (AF64A) in vivo. J Pharmacol Exp Ther 222:140–145.
Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhib-
itor p21 in apoptosis. Mol Cancer Ther 1:639–649.
Gorman AM, Hirt UA, Orenius S, Ceccatelli S (2000) Dexamethasone pre-
treatment interferes with apoptotic death in glioma cells. Neuroscience
96:417–425.
Greene LA, Biswas SC, Liu DX (2004) Cell cycle molecules and vertebrate
neuron death: E2F at the hub. Cell Death Differ 11:49–60.
Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FB, Plumier J-C, Reb-
samenMC, Hsieh C-M, Chui D-S, Thomas KL, Prorock AJ, Laubach VE,
Moskowitz MA, French BA, Ley K, Liao JK (2002) Acute cardiovascular
protective effects of corticosteroids are mediated by non-transcriptional
activation of endothelial nitric oxide synthase. Nat Med 8:473–479.
Harms C, Lautenschlager M, Bergk A, Freyer D, Weih M, Dirnagl U, Weber
JR, Hortnagl H (2000) Melatonin is protective in necrotic but not in
caspase-dependent, free radical-independent apoptotic neuronal cell
death in primary neuronal cultures. FASEB J 14:1814–1824.
Harms C, Lautenschlager M, Bergk A, Katchanov J, Freyer D, Kapinya K,
Herwig U, Megow D, Dirnagl U, Weber JR, Hortnagl H (2001) Differ-
ential mechanisms of neuroprotection by 17 -estradiol in apoptotic ver-
sus necrotic neurodegeneration. J Neurosci 21:2600–2609.
HarmsC, Bosel J, LautenschlagerM,HarmsU, Braun JS,HortnaglH,Dirnagl
Figure 6. Ectopic expression of p21Waf1/Cip1 is neuroprotective and enhances the positive effects of corticosterone. A, Rat
cortical neuronswere adenovirally transducedwith p21Waf1/Cip1 or-Gal as a control and/or 50M corticosterone (Cort.). At 20 h
after transfection,AF64Awasadded. Cellswere fixed48hafter additionofAF64A. For immunostaining, cellswere stainedwith the
neuronal marker Map-2 (red) and the nuclear counterstain Hoechst (blue). Scale bar, 30 m. B, Neurons were stained with
antibodies raised against the neuronal marker Map-2 (red). Nuclear morphology was revealed by Hoechst staining. Cell counts of
viable neurons were performed as described in Materials and Methods. *p 0.001 versus AF64A plus Cort. plus-Gal-treated
cultures; p 0.05 versus AF64A plus p21Waf1/Cip1; one-way ANOVA followed by Tukey’s post hoc test. C, Loss of dendritic
network was prevented by additive treatment with ectopic p21Waf1/Cip1 and 50 M Cort. Higher magnification of A revealed
differences in the intensity of Map-2 staining and the dendritic network after treatment with either ectopic p21Waf1/Cip1 or
p21Waf1/Cip1 plus Cort. Scale bar, 30m.
4570 • J. Neurosci., April 25, 2007 • 27(17):4562–4571 Harms et al. • Neuroprotection by Glucocorticoids; Role of p21
U, Kwiatkowski DJ, Fink K, Endres M (2004) Neuronal gelsolin pre-
vents apoptosis by enhancing actin depolymerization. Mol Cell Neurosci
25:69–82.
Hauck L, Hansmann G, Dietz R, von Harsdorf R (2002) Inhibition of
hypoxia-induced apoptosis by modulation of retinoblastoma protein-
dependent signaling in cardiomyocytes. Circ Res 91:782–789.
Katchanov J, Harms C, Gertz K, Hauck L, Waeber C, Hirt L, Priller J, von
Harsdorf R, Bruck W, Hortnagl H, Dirnagl U, Bhide PG, Endres M
(2001) Mild cerebral ischemia induces loss of cyclin-dependent kinase
inhibitors and activation of cell cycle machinery before delayed neuronal
cell death. J Neurosci 21:5045–5053.
Koh JY, Choi DW (1987) Quantitative determination of glutamate medi-
ated cortical neuronal injury in cell culture by lactate dehydrogenase ef-
flux assay. J Neurosci Methods 20:83–90.
Lautenschlager M, Onufriev MV, Gulyaeva NV, Harms C, Freyer D, Sehms-
dorf U, Ruscher K, Moiseeva YV, Arnswald A, Victorov I, Dirnagl U,
Weber JR, Hortnagl H (2000) Role of nitric oxide in the ethylcholine
aziridiniummodel of delayed apoptotic neurodegeneration in vivo and in
vitro. Neuroscience 97:383–393.
Lee AL, OgleWO, Sapolsky RM (2002) Stress and depression: possible links
to neuron death in the hippocampus. Bipolar Disord 4:117–128.
Li C-H, Tzeng S-L, Cheng Y-W, Kang J-J (2005) Chloramphenicol-induced
mitochondrial stress increases p21 expression and prevents cell apoptosis
through a p21-dependent pathway. J Biol Chem 280:26193–26199.
Limbourg FP,HuangZ, Plumier J-C, Simoncini T, FujiokaM, Tuckermann J,
Schu¨tz G, Moskowitz MA, Liao JK (2002) Rapid nontranscriptional ac-
tivation of endothelial nitric oxide synthase mediates increased cerebral
blood flow and stroke protection by corticoids. J Clin Invest
110:1729–1738.
Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Es-
hraghi M, Manda KD,Wiechec E, Los M (2007) Cell survival, cell death
and cell cycle pathways are interconnected: implications for cancer ther-
apy. Drug Resist Updat, in press.
McCullers DL, Sullivan PG, Scheff SW, Herman JP (2002) Mifepristone
protects CA1 hippocampal neurons following traumatic brain injury in
rat. Neuroscience 109:219–230.
Melcangi RC, Cavaretta I, Magnaghi V, Ciusani E, Salmaggi A (2000) Cor-
ticosteroids protect oligodendrocytes from cytokine-induced cell death.
NeuroReport 11:3969–3972.
Porter AG (1999) Protein translocation in apoptosis. Trends Cell Biol
9:394–401.
Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, Kapinya K,
Dirnagl U, Meisel A (2003) Hypoxia-induced stroke tolerance in the
mouse is mediated by erythropoietin. Stroke 34:1981–1986.
RamalingamA,Hirai A, Thompson EA (1997) Glucocorticoid inhibition of
fibroblast proliferation and regulation of the cyclin kinase inhibitor
p21Cip1. Mol Endocrinol 11:577–586.
Ro¨ssig L, Badorff C, Holzmann Y, Zeiher AM,Dimmeler S (2002) Glycogen
synthase kinase-3 couples AKT-dependent signaling to the regulation of
p21Cip1 degradation. J Biol Chem 277:9684–9689.
Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J,
Dirnagl U, Meisel A (2002) Erythropoietin is a paracrine mediator of
ischemic tolerance in the brain: evidence from an in vitro model. J Neu-
rosci 22:10291–10301.
Sasson R, Tajima K, Amsterdam A (2001) Glucocorticoids protect against
apoptosis induced by serum deprivation, cyclic adenosine 3,5-
monophosphate and p53 activation in immortalized human granulosa
cells: involvement of Bcl-2. Endocrinology 142:802–811.
Sasson R,Winder N, Kees S, AmsterdamA (2002) Induction of apoptosis in
granulosa cells by TNF  and its attenuation by glucocorticoids involve
modulation of Bcl-2. Biochem Biophys Res Commun 294:51–59.
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK
(2000) Interaction of estrogen receptor with the regulatory subunit of
phosphatidylinositol-3-OH kinase. Nature 407:538–541.
Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M (1998) Resistance to
Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle
regulator p21WAF1 and IAP gene family ILP. Oncogene 17:931–939.
Suzuki A, Tsutomi Y, Miura M, Akahane K (1999a) Caspase 3 inactivation
to suppress Fas-mediated apoptosis: identification of binding domain
with p21 and ILP and inactivation machinery by p21. Oncogene
18:1239–1244.
Suzuki A, Tsutomi Y, Yamamoto N, Shibutani T, Akahane K (1999b) Mito-
chondrial regulation of cell death: mitochondria are essential for pro-
caspase 3-p21 complex formation to resist Fas-mediated cell death. Mol
Cell Biol 19:3842–3847.
Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K
(2000) Procaspase 3/p21 complex formation to resist fas-mediated cell
death is initiated as a result of the phosphorylation of p21 by protein
kinase A. Cell Death Differ 7:721–728.
Terada Y, Okado T, Inoshita S, Hanada S, Kuwahara M, Sasaki S, Yamamoto
T,Marumo F (2001) Glucocorticoids stimulate p21(CIP1) inmesangial
cells and in anti-GBM glomerulonephritis. Kidney Int 59:1706–1716.
Tuor UI (1997) Glucocorticoids and the prevention of hypoxic-ischemic
brain damage. Neurosci Biobehav Rev 21:175–179.
von Harsdorf R, Hauck L, Mehrhof F, Wegenka U, Cardoso MC, Dietz R
(1999) E2F-1 overexpression in cardiomyocytes induces downregulation
of p21CIP1 and p27KIP1 and release of active cyclin-dependent kinases in
the presence of insulin-like growth factor I. Circ Res 85:128–136.
Wenzel A, GrimmC, SeeligerMW, Jaissle G,Hafezi F, Kretschmer R, Zrenner
E, Reme´ CE (2001) Prevention of photoreceptor apoptosis by activation
of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 42:1653–1659.
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC (2001) Cytoplasmic
localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-
2/neu-overexpressing cells. Nat Cell Biol 3:245–252.
Harms et al. • Neuroprotection by Glucocorticoids; Role of p21 J. Neurosci., April 25, 2007 • 27(17):4562–4571 • 4571
